All Oncology News

A response to neoadjuvant chemotherapy was associated with long-term survival benefits in high-risk UTUC.

Sac-TMT produced durable responses with a manageable safety profile in pretreated advanced/metastatic urothelial carcinoma.

Post-treatment ctDNA positivity was associated with disease recurrence in locoregionally advanced HNSCC, including p16-positive oropharynx cancer.

The 5-year OS rate favored tebentafusp vs investigator’s choice of therapy in HLA-A*02:01–positive uveal melanoma.

Toni Choueiri, MD, of Dana-Farber Cancer Institute, was elected to The Association of American Physicians.

Pembrolizumab plus lenvatinib and belzutifan, as well as pembrolizumab/quavonlimab plus lenvatinib, did not extend OS or PFS in first-line ccRCC.

Maurie Markman, MD, highlights the frequently complex arena of goals of care discussions in oncology.

China’s NMPA approved belantamab mafodotin plus Vd for the treatment of relapsed/refractory multiple myeloma after at least 1 prior line of therapy.

Bortezomib maintenance was associated with lower rates of moderate-to-severe cGVHD in newly diagnosed multiple myeloma after allo-HSCT.

Cilta-cel demonstrated feasibility in the treatment of patients with high-risk smoldering multiple myeloma in the phase 2 CAR-PRISM trial.

Molecular testing identified actionable alterations in high proportions of patients with breast and colorectal cancers, regardless of ctDNA status.

Zoldonrasib produced responses and no grade 4 or 5 TRAEs in previously treated KRAS G12D–mutated NSCLC.

Daniel Johnson, MD, discusses the use of TIL therapy in melanoma, including patient selection, sequencing, timing, and emerging applications beyond skin cancer.

Roswell Park Comprehensive Cancer Center launched a trial of a new CAR T-cell therapy for AML that has relapsed or persisted despite earlier treatment.

The FDA has granted priority review to the sBLAs for pembrolizumab and subcutaneous pembrolizumab plus enfortumab vedotin in cisplatin-eligible MIBC.

Sharon Castellino, MD, MSc, discusses the significance of the FDA approval of nivolumab plus AVD for stage III/IV classical Hodgkin lymphoma.

Relapse following allo-HSCT remains frequent and represents an ongoing therapeutic challenge for patients with myelofibrosis or BP-MPNs.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, endometrial cancer, salivary gland cancer, myeloproliferative neoplasms, and renal cell carcinoma.

Experts from across oncology specialties highlight research being presented at the 2026 AACR Annual Meeting.

The FDA granted priority review to an I-DXd BLA for extensive-stage small cell lung cancer, a sBLA for zenocutuzumab in NRG1+ cholangiocarcinoma has been submitted to the FDA, and more.

With burnout and conference attendance prevalent across the oncology community, oncology professionals strive to enact positive changes.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Gynecologic oncologists share their top data picks from SGO 2026, including ROSELLA, KEYNOTE-B96, NRG-GY019, and more.

A new model explains how genetic information is not just stored but continuously used to keep cells organized and functioning.

Dallas Gallagher, DNP, FNP-C, AOCNP, discusses individualized chemotherapy selection and the importance of a "person-first" approach to pancreatic cancer care.

Joshua Lang, MD, MS, discusses the rationale for, and design of, the MEVPRO-1 and MEVPRO-2 studies in mCRPC.

Jennifer Wargo, MD, of The University of Texas MD Anderson Cancer Center, has been elected to the 2026 class of Fellows of the American Association for Cancer Research (AACR) Academy.

Christine M. Lovly, MD, PhD, FASCO, discuses acquired resistance in EGFR-mutated NSCLC, including detection and novel approaches to address it.

Multipeptide vaccines in combination with BTK inhibitor–based regimens yielded safety and potent T-cell responses in chronic lymphocytic leukemia.

Susan Scott, MD, Julia Rotow, MD, and Enriqueta Felip, MD, PhD, debate the optimal choice of frontline regimen for EGFR-mutated NSCLC.